Cover Image
Market Research Report

Pulmonary Edema Therapeutics Market by Type and Geography - Forecast and Analysis 2019-2023

Published by TechNavio (Infiniti Research Ltd.) Product code 914206
Published Content info 153 Pages
Delivery time: 1-2 business days
Price
Back to Top
Pulmonary Edema Therapeutics Market by Type and Geography - Forecast and Analysis 2019-2023
Published: October 13, 2019 Content info: 153 Pages
Description

About this market

Technavio's pulmonary edema therapeutics market analysis considers sales from cardiogenic pulmonary edema and non-cardiogenic pulmonary edema types. Our study also finds the sales of pulmonary edema therapeutics in Asia, Europe, North America, and ROW. In 2018, the cardiogenic pulmonary edema segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the high prevalence of cardiovascular diseases such as carotid artery disease, cardiomyopathy, heart valve problems, and hypertension will play a significant role in the cardiogenic pulmonary edema segment to maintain its market position. Also, our global pulmonary edema therapeutics market report looks at factors such as high prevalence of risk factors, increasing geriatric population, and growing awareness about pulmonary edema. However, adverse effects of available therapeutics, high level of genericization in the market, and availability of substitutes may hamper the growth of the pulmonary edema therapeutics industry over the forecast period.

Overview

High prevalence of risk factors

Pulmonary edema is one of the leading causes of death in adults living in developing countries. The high incidence of pulmonary edema is mainly attributed to the availability of high-risk factors such as infections, organ failures, lifestyle habits, trauma, and high altitude. Pulmonary edema can also be caused due to the potential overdosage of drugs such as aspirin and chemotherapy drugs. This high prevalence of risk factors will lead to the expansion of the global pulmonary edema therapeutics market at a CAGR of almost 3% during the forecast period.

Increasing the use of biomarkers for disease diagnosis

The detection of pulmonary edema through biomarkers is gaining prominence in recent diagnostic evaluations. A biomarker is a measurable indicator of a specific biological state or condition, including a pathogenic process. Pulmonary edema is diagnosed by clinical evaluation and imaging tests, which are the most common methods. Blood tests also play a crucial role in identifying the disease through biomarkers present in the blood. The use of biomarkers is less expensive than other evaluation tests. Moreover, these makers can detect other heart or kidney-related diseases. This development is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global pulmonary edema therapeutics market during the forecast period 2019-2023, view our report.

Competitive Landscape

With the presence of several major players, the global pulmonary edema therapeutics market is moderately fragmented. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading pulmonary edema therapeutics manufacturers, that include AbbVie Inc., Bausch Health Companies Inc., Johnson & Johnson Services Inc., Lupin Ltd., Merck & Co. Inc., Mylan NV, Novartis AG, Pfizer Inc., Sanofi, and Teva Pharmaceutical Industries Ltd.

Also, the pulmonary edema therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

Table of Contents
Product Code: IRTNTR32178

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY TYPE

  • Market segmentation by type
  • Comparison by type
  • Cardiogenic pulmonary edema - Market size and forecast 2018-2023
  • Non-cardiogenic pulmonary edema - Market size and forecast 2018-2023
  • Market opportunity by type

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • Increasing use of biomarkers for disease diagnosis
  • Strategic alliances
  • Increase in funding for research on respiratory diseases

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AbbVie Inc.
  • Bausch Health Companies, Inc.
  • Johnson & Johnson Services Inc.
  • Lupin Ltd.
  • Merck & Co., Inc.
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

LIST OF EXHIBITS:

  • Exhibit 01: Product overview
  • Exhibit 02: Global pharmaceuticals market
  • Exhibit 03: Segments of global pharmaceuticals market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: Product - Market share 2018-2023 (%)
  • Exhibit 19: Comparison by type
  • Exhibit 20: Cardiogenic pulmonary edema - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 21: Cardiogenic pulmonary edema - Year-over-year growth 2019-2023 (%)
  • Exhibit 22: Non-cardiogenic pulmonary edema - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 23: Non-cardiogenic pulmonary edema - Year-over-year growth 2019-2023 (%)
  • Exhibit 24: Market opportunity by type
  • Exhibit 25: Customer landscape
  • Exhibit 26: Market share by geography 2018-2023 (%)
  • Exhibit 27: Geographic comparison
  • Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 30: Top 3 countries in North America
  • Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 33: Top 3 countries in Europe
  • Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 35: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 36: Top 3 countries in Asia
  • Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 38: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 39: Top 3 countries in ROW
  • Exhibit 40: Key leading countries
  • Exhibit 41: Market opportunity
  • Exhibit 42: Impact of drivers and challenges
  • Exhibit 43: Vendor landscape
  • Exhibit 44: Landscape disruption
  • Exhibit 45: Vendors covered
  • Exhibit 46: Vendor classification
  • Exhibit 47: Market positioning of vendors
  • Exhibit 48: AbbVie Inc. - Vendor overview
  • Exhibit 49: AbbVie Inc. - Business segments
  • Exhibit 50: AbbVie Inc. - Organizational developments
  • Exhibit 51: AbbVie Inc. - Geographic focus
  • Exhibit 52: AbbVie Inc. - Key offerings
  • Exhibit 53: AbbVie Inc. - Key customers
  • Exhibit 54: Bausch Health Companies Inc. - Vendor overview
  • Exhibit 55: Bausch Health Companies Inc. - Business segments
  • Exhibit 56: Bausch Health Companies Inc. - Organizational developments
  • Exhibit 57: Bausch Health Companies Inc. - Geographic focus
  • Exhibit 58: Bausch Health Companies Inc. - Segment focus
  • Exhibit 59: Bausch Health Companies Inc. - Key offerings
  • Exhibit 60: Bausch Health Companies Inc. - Key customers
  • Exhibit 61: Johnson & Johnson Services, Inc. - Vendor overview
  • Exhibit 62: Johnson & Johnson Services, Inc. - Business segments
  • Exhibit 63: Johnson & Johnson Services, Inc. - Organizational developments
  • Exhibit 64: Johnson & Johnson Services, Inc. - Geographic focus
  • Exhibit 65: Johnson & Johnson Services, Inc. - Segment focus
  • Exhibit 66: Johnson & Johnson Services, Inc. - Key offerings
  • Exhibit 67: Johnson & Johnson Services, Inc. - Key customers
  • Exhibit 68: Lupin Ltd. - Vendor overview
  • Exhibit 69: Lupin Ltd. - Business segments
  • Exhibit 70: Lupin Ltd. - Organizational developments
  • Exhibit 71: Lupin Ltd. - Geographic focus
  • Exhibit 72: Lupin Ltd. - Key offerings
  • Exhibit 73: Lupin Ltd. - Key customers
  • Exhibit 74: Merck & Co. Inc. - Vendor overview
  • Exhibit 75: Merck & Co. Inc. - Business segments
  • Exhibit 76: Merck & Co. Inc. - Organizational developments
  • Exhibit 77: Merck & Co. Inc. - Geographic focus
  • Exhibit 78: Merck & Co. Inc. - Segment focus
  • Exhibit 79: Merck & Co. Inc. - Key offerings
  • Exhibit 80: Merck & Co. Inc. - Key customers
  • Exhibit 81: Mylan NV - Vendor overview
  • Exhibit 82: Mylan NV - Product segments
  • Exhibit 83: Mylan NV - Organizational developments
  • Exhibit 84: Mylan NV - Geographic focus
  • Exhibit 85: Mylan NV - Segment focus
  • Exhibit 86: Mylan NV - Key offerings
  • Exhibit 87: Mylan NV - Key customers
  • Exhibit 88: Novartis AG - Vendor overview
  • Exhibit 89: Novartis AG - Business segments
  • Exhibit 90: Novartis AG - Organizational developments
  • Exhibit 91: Novartis AG - Geographic focus
  • Exhibit 92: Novartis AG - Segment focus
  • Exhibit 93: Novartis AG - Key offerings
  • Exhibit 94: Novartis AG - Key customers
  • Exhibit 95: Pfizer Inc. - Vendor overview
  • Exhibit 96: Pfizer Inc. - Business segments
  • Exhibit 97: Pfizer Inc. - Organizational developments
  • Exhibit 98: Pfizer Inc. - Geographic focus
  • Exhibit 99: Pfizer Inc. - Segment focus
  • Exhibit 100: Pfizer Inc. - Key offerings
  • Exhibit 101: Pfizer Inc. - Key customers
  • Exhibit 102: Sanofi - Vendor overview
  • Exhibit 103: Sanofi - Business segments
  • Exhibit 104: Sanofi - Organizational developments
  • Exhibit 105: Sanofi - Geographic focus
  • Exhibit 106: Sanofi - Segment focus
  • Exhibit 107: Sanofi - Key offerings
  • Exhibit 108: Sanofi - Key customers
  • Exhibit 109: Teva Pharmaceutical Industries Ltd. - Vendor overview
  • Exhibit 110: Teva Pharmaceutical Industries Ltd. - Business segments
  • Exhibit 111: Teva Pharmaceutical Industries Ltd. - Organizational developments
  • Exhibit 112: Teva Pharmaceutical Industries Ltd. - Segment focus
  • Exhibit 113: Teva Pharmaceutical Industries Ltd. - Key offerings
  • Exhibit 114: Teva Pharmaceutical Industries Ltd. - Key customers
  • Exhibit 115: Validation techniques employed for market sizing
  • Exhibit 116: Definition of market positioning of vendors
Back to Top